APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

• Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431
• Inhibitors discovered at Domainex via virtual and fragment screening

Press release (EN) | Presseaussendung (DE)